Chemistry42 and Pharma.AI (Insilico)
Generative chemistry platform behind the first AI-discovered drug to reach phase 2, plus oncology candidates.
Insilico's rentosertib (TNIK, IPF) reported phase 2a results in 2025; oncology programmes include ISM3091 (USP1, licensed to Exelixis) and ISM5411.
How it works
Generative models for target discovery, molecule generation and trial outcome prediction.
- Clinical-stage validation of the platform
- Oncology assets early
Latest papers
topQuery for this technology: (TITLE:"Chemistry42 and Pharma.AI" OR ABSTRACT:"Chemistry42 and Pharma.AI" OR TITLE:"Insilico" OR ABSTRACT:"Insilico") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Chemistry42 and Pharma.AI (Insilico), not a curated reading list.
Pages like this
not linked directly; found by shared links- IdeaIn silico trials to choose the dose before the first patient
Shares Insilico Medicine, AI-driven drug & target discovery.
- IdeaA virtual cancer cell that predicts what a drug will do before you test it
Shares Insilico Medicine, AI-driven drug & target discovery.
- TechnologyDe novo designed protein binders
Shares Insilico Medicine, AI-driven drug & target discovery.